Lansocel

Lansoprazole, the active ingredient in Lansocel, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑esophageal reflux disease, peptic ulcer disease, erosive esophagitis, and in combination regimens for Helicobacter pylori eradication.

GNH USA supplies Lansocel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansocel, a proton pump inhibitor, acts on the gastric acid secretion pathway to manage acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing by lowering gastric acidity. - Erosive esophagitis: reduces inflammation and promotes mucosal recovery. - Helicobacter pylori eradication (in combination therapy): enhances eradication rates when used with antibiotics and a bismuth compound.

Lansocel may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools, usually transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: cramp‑like discomfort. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis. - Severe allergic reactions: rash, swelling, anaphylaxis. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: skin detachment. - Hepatic enzyme elevation: potential liver injury. - Hypomagnesemia: low serum magnesium with prolonged use. - Increased risk of bone fractures: especially with long‑term therapy.

Before prescribing Lansocel, clinicians should consider several safety aspects.

- Renal function assessment: adjust use in severe impairment. - Monitor for infections: especially gastrointestinal C. difficile. - Use with caution in elderly patients: higher risk of fractures. - Avoid abrupt discontinuation: may cause rebound acid hypersecretion. - Periodic magnesium level checks: especially with long‑term therapy. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lansocel can affect the pharmacokinetics of several medicines, requiring careful management.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased absorption, leading to subtherapeutic antiviral levels. - High‑dose methotrexate: increased toxicity due to reduced clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Digoxin: may raise serum concentrations, necessitating dosage adjustment. - Diazepam: elevated levels may enhance sedation, monitor patient response.